Pros and cons of a prion-like pathogenesis in parkinson's disease

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Hilker, Ruediger ^a   Brotchie, Jonathan M ^b   Chapman, Joab ^c  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; PRION PROTEIN;

ARTICLE; BRAIN DEGENERATION; BRAIN TRANSPLANTATION; CELL TRANSPLANTATION; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; CLINICAL FEATURE; CREUTZFELDT JAKOB DISEASE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DURA MATER; ELECTROENCEPHALOGRAPHY; EMBRYO CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LEWY BODY; MOLECULAR BIOLOGY; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOGENESIS; PRION DISEASE; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN STRUCTURE; METABOLISM; NERVE DEGENERATION; PATHOLOGY; PRION;

ALPHA-SYNUCLEIN; HUMANS; NERVE DEGENERATION; PARKINSON DISEASE; PRIONS;

EID: 79959265857     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-74     Document Type: Article

References (40)

1. Jellinger KA. Neuropathological aspects of alzheimer disease, parkinson disease and frontotemporal dementia. Neurodegener Dis 2008, 5:118-121. 10.1159/000113679, 18322367.
2. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in parkinson's disease. Brain 2009, 132:2947-2957. 10.1093/brain/awp234, 19759203.
3. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. Failure of the ubiquitin-proteasome system in parkinson's disease. Nat Rev Neurosci 2001, 2:589-594.
4. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 2009, 106:13010-13015. 10.1073/pnas.0903691106, 2722313, 19651612.
5. Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B. Aggregated and monomeric alpha-synuclein bind to the s6' proteasomal protein and inhibit proteasomal function. J Biol Chem 2003, 278:11753-11759. 10.1074/jbc.M208641200, 12551928.
6. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in parkinson's disease. Nat Med 2008, 14:504-506. 10.1038/nm1747, 18391962.
7. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, Brundin P. Lewy bodies in grafted neurons in subjects with parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008, 14:501-503. 10.1038/nm1746, 18391963.
8. Olanow CW, Prusiner SB. Is parkinson's disease a prion disorder?. Proc Natl Acad Sci USA 2009, 106:12571-12572. 10.1073/pnas.0906759106, 2722298, 19666621.
9. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998, 95:13363-13383. 10.1073/pnas.95.23.13363, 33918, 9811807.
10. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE, et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 1993, 90:10962-10966. 10.1073/pnas.90.23.10962, 47901, 7902575.
11. Prusiner SB. Shattuck lecture--neurodegenerative diseases and prions. N Engl J Med 2001, 344:1516-1526. 10.1056/NEJM200105173442006, 11357156.
12. McKinley MP, Meyer RK, Kenaga L, Rahbar F, Cotter R, Serban A, Prusiner SB. Scrapie prion rod formation in vitro requires both detergent extraction and limited proteolysis. J Virol 1991, 65:1340-1351. 239910, 1704926.
13. Holman RC, Khan AS, Belay ED, Schonberger LB. Creutzfeldt-jakob disease in the united states, 1979-1994: Using national mortality data to assess the possible occurrence of variant cases. Emerg Infect Dis 1996, 2:333-337. 10.3201/eid0204.960409, 2639929, 8969250.
14. DeArmond SJ, Ironside WJ. Neuropathology of prion diseases. Prion biology and diseases 1999, 585-652. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press, Prusiner SB.
15. DeArmond SJ, McKinley MP, Barry RA, Braunfeld MB, McColloch JR, Prusiner SB. Identification of prion amyloid filaments in scrapie-infected brain. Cell 1985, 41:221-235. 10.1016/0092-8674(85)90076-5, 3922627.
16. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of lewy bodies from parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 1998, 95:6469-6473. 10.1073/pnas.95.11.6469, 27806, 9600990.
17. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in lewy bodies. Nature 1997, 388:839-840. 10.1038/42166, 9278044.
18. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with parkinson's disease. Science 1997, 276:2045-2047. 10.1126/science.276.5321.2045, 9197268.
19. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A. Alpha-synuclein locus duplication as a cause of familial parkinson's disease. Lancet 2004, 364:1167-1169. 10.1016/S0140-6736(04)17103-1, 15451224.
20. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. Alpha-synuclein locus triplication causes parkinson's disease. Science 2003, 302:841. 10.1126/science.1090278, 14593171.
21. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in lysosomal and proteasomal markers in parkinson's disease: Relationship to alpha-synuclein inclusions. Neurobiol Dis 2009, 35:385-398. 10.1016/j.nbd.2009.05.023, 19505575.
22. Rideout HJ, Larsen KE, Sulzer D, Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in pc12 cells. J Neurochem 2001, 78:899-908. 10.1046/j.1471-4159.2001.00474.x, 11520910.
23. Cookson MR, van der Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 2008, 209:5-11. 10.1016/j.expneurol.2007.05.022, 2231843, 17603039.
24. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset parkinson disease. Nat Med 1998, 4:1318-1320. 10.1038/3311, 9809558.
25. Ferreon AC, Gambin Y, Lemke EA, Deniz AA. Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence. Proc Natl Acad Sci USA 2009, 106:5645-5650. 10.1073/pnas.0809232106, 2667048, 19293380.
26. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic parkinson's disease. Neurobiol Aging 2003, 24:197-211. 10.1016/S0197-4580(02)00065-9, 12498954.
27. Windl O, Giese A, Schulz-Schaeffer W, Zerr I, Skworc K, Arendt S, Oberdieck C, Bodemer M, Poser S, Kretzschmar HA. Molecular genetics of human prion diseases in germany. Hum Genet 1999, 105:244-252. 10.1007/s004390051096, 10987652.
28. Piccardo P, Dlouhy SR, Lievens PM, Young K, Bird TD, Nochlin D, Dickson DW, Vinters HV, Zimmerman TR, Mackenzie IR, Kish SJ, Ang LC, De Carli C, Pocchiari M, Brown P, Gibbs CJ, Gajdusek DC, Bugiani O, Ironside J, Tagliavini F, Ghetti B. Phenotypic variability of gerstmann-straussler-scheinker disease is associated with prion protein heterogeneity. J Neuropathol Exp Neurol 1998, 57:979-988. 10.1097/00005072-199810000-00010, 9786248.
29. Mead S. Prion disease genetics. Eur J Hum Genet 2006, 14:273-281. 10.1038/sj.ejhg.5201544, 16391566.
30. Gasser T. Update on the genetics of parkinson's disease. Mov Disord 2007, 22:S343-S350. 10.1002/mds.21676, 18175395.
31. Goedert M, Spillantini MG, Davies SW. Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Opin Neurobiol 1998, 8:619-632. 10.1016/S0959-4388(98)80090-1, 9811617.
32. Miller DW, Hague SM, Clarimon J, Baptista M, Gwinn-Hardy K, Cookson MR, Singleton AB. Alpha-synuclein in blood and brain from familial parkinson disease with snca locus triplication. Neurology 2004, 62:1835-1838.
33. Dawson TM, Ko HS, Dawson VL. Genetic animal models of parkinson's disease. Neuron 2010, 66:646-661. 10.1016/j.neuron.2010.04.034, 2917798, 20547124.
34. Solomon IH, Schepker JA, Harris DA. Prion neurotoxicity: Insights from prion protein mutants. Curr Issues Mol Biol 2010, 12:51-61.
35. Medrano AZ, Barmada SJ, Biasini E, Harris DA. Gfp-tagged mutant prion protein forms intra-axonal aggregates in transgenic mice. Neurobiol Dis 2008, 31:20-32. 10.1016/j.nbd.2008.03.006, 2536573, 18514536.
36. Chesselet MF. In vivo alpha-synuclein overexpression in rodents: A useful model of parkinson's disease?. Exp Neurol 2008, 209:22-27. 10.1016/j.expneurol.2007.08.006, 2262051, 17949715.
37. Chesselet MF, Fleming S, Mortazavi F, Meurers B. Strengths and limitations of genetic mouse models of parkinson's disease. Parkinsonism Relat Disord 2008, 14(Suppl 2):S84-87. 2577895, 18585084.
38. Fournier JG. Cellular prion protein electron microscopy: Attempts/limits and clues to a synaptic trait. Implications in neurodegeneration process. Cell Tissue Res 2008, 332:1-11. 10.1007/s00441-007-0565-5, 18236081.
39. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM, Schlossmacher MG. Direct quantification of csf alpha-synuclein by elisa and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008, 213:315-325. 10.1016/j.expneurol.2008.06.004, 18625222.
40. Brown K, Mastrianni JA. The prion diseases. J Geriatr Psychiatry Neurol 2010, 23:277-298. 10.1177/0891988710383576, 20938044.